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A B S T R A C T
Background: The Italian Society of Clinical Biochemistry (SIBioC) and the Italian Section of the European Ligand
Assay Society (ELAS) have recently promoted a multicenter study (Italian hs-cTnI Study) with the aim to ac-
curately evaluate analytical performances and reference values of the most popular cTnI methods commercially
available in Italy. The aim of this article is to report the results of the Italian hs-cTnI Study concerning the
evaluation of the 99th percentile URL and reference change (RCV) values around the 99th URL of the Access cTnI
method.
Materials and methods: Heparinized plasma samples were collected from 1306 healthy adult volunteers by 8
Italian clinical centers. Every center collected from 50 to 150 plasma samples from healthy adult subjects. All
volunteers denied the presence of chronic or acute diseases and had normal values of routine laboratory tests
(including creatinine, electrolytes, glucose and blood counts). An older cohort of 457 adult subjects (mean age
63.0 years; SD 8.1 years, minimum 47 years, maximum 86 years) underwent also ECG and cardiac imaging
analysis in order to exclude the presence of asymptomatic cardiac disease.
Results and conclusions: The results of the present study confirm that the Access hsTnI method using the DxI
platform satisfies the two criteria required by international guidelines for high-sensitivity methods for cTn assay.
Furthermore, the results of this study confirm that the calculation of the 99th percentile URL values are greatly
affected not only by age and sex of the reference population, but also by the statistical approach used for
calculation of cTnI distribution parameters.
1. Introduction
Cardiac troponin I (cTnI) and T (cTnT) are the preferred biomarker
for the differential diagnosis of acute coronary syndrome (ACS) [1–3].
International guidelines recommended that the increase in cTnI or cTnT
levels over the 99th percentile upper reference limit (99th URL) should
be considered as clinically relevant, and they also specifically indicated
that this cut off value should be measured with an imprecision ≤10 CV
% [1–3]. Only after the year 2006, some manufacturers set-up the first
new generation of cTnI and cTnT immunoassays with improved
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analytical sensitivity with the aim to satisfy the quality specifications
requested by international guidelines and consensus documents [4–14].
The 2018 Expert Opinion from the AACC and IFCC [2] recommends
that high-sensitivity methods for cTnI and cTnT assay should satisfy
two fundamental criteria. First, high-sensitivity methods should mea-
sure the 99th percentile URL with an imprecision (expressed as CV %)
≤10%. Second, high-sensitivity methods should measure cTn con-
centrations above the LoD of the method at least in 50% healthy sub-
jects enrolled in large populations including>300 men and 300
women [2]. The 99th URL values not only strongly depend on demo-
graphic and physiological variables of populations (i.e., the criteria for
considering the reference population “healthy”), but also on the ana-
lytical performances of cTnI methods, as well as on the mathematical
algorithms used for calculating the 99th percentile URL [15,16].
In 2016, the guidelines of European Society of Cardiology (ESC) on
the management of acute coronary syndromes (ACS) in patients pre-
senting without persistent ST-segment elevation (NSTEMI) suggested
0 h/1 h rule-in and rule-out algorithms when measurement of cardiac
troponins is performed using high-sensitivity immunoassay methods
[1]. These guidelines recommend the use of absolute change (i.e., ex-
pressed as difference in cTn concentrations, ng/L) rather than percen-
tage variation for the assessment of the rise and/or fall of cTn values
[1].
According to the claims of international guidelines [1–3], the Italian
Society of Clinical Biochemistry (SIBioC) and the Italian Section of the
European Ligand Assay Society (ELAS) have recently promoted a mul-
ticenter study (named Italian hs-cTnI Study) with the aim to accurately
evaluate analytical performances and reference values of the most
popular cTnI methods commercially available in Italy. The most im-
portant aims of this article are to report and discuss the results of the
Italian hs-cTnI Study concerning the evaluation of the 99th percentile
URL and reference change (RCV) values around the 99th URL of the
Access method, for cTnI assay using UniCell DxI 800 automated plat-
form (named Access hsTnI, REF B52699), recently distributed to the
Italian clinical laboratories.
2. Materials and methods
2.1. Reference population and plasma sample collection
The Italian hs-cTnI Study is a multicenter clinical study.
Heparinized plasma samples were collected from a total of 1306
healthy adult volunteers by 8 Italian clinical centers, including both
University and Regional Hospitals, which have highly qualified work-
force staff in emergency, cardiology and laboratory departments. Every
center collected from 50 to 150 plasma samples from healthy adult
subjects enrolled from the clinical and laboratory staff or volunteers
blood donors with age from 18 to 86 years.
All volunteers denied the presence of chronic or acute diseases and
had normal values of routine laboratory tests (including creatinine,
electrolytes, glucose and blood counts) [17]. In particular, to more
accurately evaluate cTnI concentrations of healthy subjects older than
47 years, plasma samples from 457 adult subjects collected in the
MEHLP study were also assayed (mean age 63.0 years; SD 8.1 years,
minimum 47 years, maximum 85 years). The MEHLP study is a
screening study aimed to evaluate the cardiovascular subclinical dis-
ease in an asymptomatic general population with age > 45 years from
the community of Montignoso (Massa, Italy), as reported in detail
elsewhere [17]. All the subjects enrolled in the MEHLP study under-
went an accurate health investigation by means of a thorough clinical
examination and routine laboratory tests [17]. Furthermore, lifestyle
habits and medical history were collected by questionnaires. Partici-
pants to the MHELP study underwent also ECG and cardiac imaging
analysis (computed tomography scan, carotid echography, echo-
cardiography). Exclusion criteria were: presence of cardiac or systemic
acute or chronic diseases, such as myocardial infarction, heart failure,
coronary heart disease, hypertension, diabetes, kidney disease, obesity,
tumour, hepatitis, BPCO, and use of drugs [17].
Every laboratory participating to the study stored at −80 °C two
aliquots of about 1mL of plasma samples collected from healthy sub-
jects in tubes identified by alphanumeric barcodes. The stored tubes
were sent to the reference laboratory of the study (Fondazione CNR
Regione Toscana G. Monasterio, Pisa Italy) using a pack with dry ice
within one months after the blood collection. Only age and the sex of
adult healthy volunteers were known by the staff of the reference la-
boratory. In the reference laboratory the clinical samples were im-
mediately stored at −80° and then the samples were measured within
three months with the Access cTnI immunoassay.
The informed consent was obtained by all subjects enrolled in the
study in accordance with the guidelines recommended by the respective
local ethical committees.
2.2. cTnI immunoassay method
The Access hsTnI (REF B52699) assay is a two-site immunometric
assay method (Beckman Coulter, Inc. Brea, CA 92821 USA). In the re-
ference laboratory of the Italian hs-cTnI Study were previously eval-
uated the analytical characteristics and performances of the Access cTnI
method [11]. The plasma samples were assayed in the reference la-
boratory according to the analytical procedures suggested by the
manufacture using the DxI 800 platform [12]. Limits of blank (LoB),
detection (LoD), and quantitation (LoQ) at 10% CV and 20% CV were
calculated according to international standardized protocols [18,19], as
previously described in details [11]. The imprecision profile was esti-
mated by repeatedly measuring 10 heparinized plasma pools collected
from healthy subjects and patients with cardiovascular diseases, as
previously reported in detail [11]. These pools with mean cTnI con-
centrations ranging from about 1 ng/L to about 50 ng/L were re-
peatedly measured in 40 different runs with at least 3 different cali-
brations using two or more lots of reagents throughout two months. To
calculate the limit of quantification (LoQ), the relationship between the
error of the measurement (expressed as CV values, Y-axis) and cTnI
concentrations (X-axis) was interpolated by means of a nonlinear re-
gression curve [11].
The Reference Change Values (RCV) were evaluated according to
Callum G. Fraser [20]. The bidirectional Z-score RCV between two re-
sults (CI 95%) were calculated by considering both the analytical
variability of the method (CVA) and the intra-individual variability
(CVI), using the formula: RCV=1.96 [2(CVA [2] + CVI2)] 1/2.
2.3. Statistical Analysis
For the evaluation and comparison of the analytical performance of
tested cTnI immunoassay methods, standard statistical analyses were
carried out using the JMP program (version 12.1.0, SAS Institute Inc.,
SAS Campus Drive, Cary, NC, USA). As cTnI circulating levels are not
normally distributed, both non-parametric and parametric tests after
logarithmic transformation (log-10) of data were used for statistical
analysis. For the calculation of mean and standard deviation (SD) only
robust methods were used. The identification of outlier values was
performed by means of the based on the interquartile range (IQR) as-
suming a log-normal distribution [21]. An outlier value was evaluated
by the formula: cTnI>Q3+3 IQR, as gating parameter; where, Q3 and
IQR respectively are the third quartile and interquartile range (Q3 – Q1)
of cTnI distribution.
The calculation of cTnI distribution and 99th percentile URL values
was performed with the JMP program using nonparametric method
(Fig. 1A), as recommended by international guidelines [2]. Lognormal
distribution using a robust method was also calculated for comparison
(Fig. 1B). The 99th percentile and the respective confidence interval
(CI) values (at 90% and 95%) were also calculated with adjusted
bootstrap percentile method according to Carpenter & Bithelll using
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random replacement and 100,000 repetitions [22].
3. Results
3.1. Analytical parameters and RCV of cTnI immunoassays
The analytical parameters of the Access cTnI method evaluated by
the reference laboratory of the study using international standardized
protocols [18,19] are reported in Table 1. For comparison, analytical
parameter values, suggested by manufacturer and two previous studies,
are also reported in Table 1 [23,24].
The RCV and absolute critical change (Δ change) values of the
Access cTnI method using DxI 800 platform in the range of cTnI con-
centrations from 2 ng/L to 40 ng/L are reported in Table 2. These
change values were calculated assuming an intra-individual variability
(CVI) in healthy adult subjects of 9%, according to Van der Linden et al.
[25]. As indicated by the imprecision profile previously reported [11],
the analytical variability per cTnI values ≥40 ng/L can be assumed to
be constant and equal to about 5%, and so the RCV 95% and 99% CI are
also constant and equal to about 29% and 38%, respectively.
3.2. cTnI distribution values of reference population
The total population with measured cTnI concentrations included
1306 individuals. According to the result of Tukey's test, the cTnI values
of 4 individuals (2 men and 2 women) were excluded as outliers from
the reference population. As a result, the population evaluated for the
calculation of cTnI reference distribution parameters consisted of 1302
healthy adults subjects (age range from 18 to 86 years), including 650
women (mean age 51.7 years, SD 14.5 years) and 652 men (mean age
51.1 years, SD 13.9 years), well matched for age (P= .4849) and sex-
ratio (F/M=0.997). The distribution of cTnI values of the reference
population was highly skewed (Fig. 1A), while log-transformed cTnI
values roughly approximated a log-normal distribution (Fig. 1B). Mean,
median and percentile values of cTnI values of the reference popula-
tion, evaluated by nonparametric method, are also reported in Table 3.
The values of 99th percentiles, calculated with bootstrap method were
also reported in Table 3. On average, women showed significantly
lower cTnI values than men (p < .0001 by Wilcoxon/Kruskal-Walls
test). The distribution parameters, respectively found in men and
women, are also reported in Table 3. Of note, 558 women (of 650,
corresponding to 85.8%) had cTnI concentrations equal or higher than
the LoD value (i.e., 1.3 ng/L), evaluated in the present study (Table 1).
Furthermore, the median of the cTnI values of women is 2.2 ng/L
(Table 3), which is the value of LoD value reported by the manufacturer
(Table 1). The number of men with cTnI ≥1.3 ng/L (i.e., the LoD value
evaluated in the present study) was 625 (of 652) corresponding to
95.8%.
3.3. Influence of age and sex on cTnI values in the reference population
Age and sex significantly influence cTnI concentrations in healthy
adult subjects, as demonstrated by means of a linear regression model
between log-transformed cTnI concentration (dependent variable) and
age and sex (independent variables) (Fig. 2 and Table 4). To better
understand the relationship between cTnI concentrations and age in
healthy adult subjects a spline regression analysis was performed. The
spline regression plot indicates that cTnI concentrations of apparently
healthy men and women are nearly constant from 18 to 55 years, and
then they progressively increase by reaching on average about 3-fold
higher cTnI values at 85 years (Fig. 3). Indeed, the 732 healthy subjects
with age≤ 55 years had significantly lower cTnI values than the 570
individuals with age > 55 years (2.7 ± 1.9 ng/L vs 4.1 ± 3.0 ng/L;
p < .0001 by Wilcoxon/Kruskal-Wallis test). Mean, median, and per-
centile values of cTnI distribution values of the whole reference popu-
lation, divided in age (i.e., ≤55 years vs> 55 years) and sex groups are
also reported in Table 3. Of note, the values of distribution parameters
for women and men with age > 55 year are not reported in Table 3
because the number of enrolled individuals was lower than 300, which
is the needed number of case required by international guidelines for an
accurate evaluation of 99th percentile URL values [2,15,16].
Fig. 1. Distribution of cTnI concentration value in 1302 healthy subjects.
Part A – Distribution of original cTnI values.
Part B – Distribution of log10-transformed cTnI values. The log-normal dis-
tribution is indicated in red color.
In the figure are also reported the median, the interquartile range (i.e., 25th and
75th percentiles as box), and the 10th and 90th percentiles. The values below
the 10th percentile and above the 90th percentile are reported with black cir-
cles. (For interpretation of the references to color in this figure legend, the
reader is referred to the web version of this article.)
Table 1










Masotti et al. 0.6 1.3 2.1 5.3 [11]
Lippi et al. 0.14 0.34 – 1.35 [23]
Pretorius et al. 0.3 0.6 – – [24]
Manufacturer 1.7 2.3 2.3 5.6 Technical
Bulletin
Table 2
Reference Change Value (RCV) and absolute critical change (Δ change) values
of the Access cTnI method using DxI 800 platform in the range of cTnI con-
centration from 2 ng/L to 40 ng/L.
cTnI concentration
(ng/L)









2 21.1 63.6 1.3 83.6 1.7
5 10.4 38.1 1.9 50.1 2.5
10 6.8 31.3 3.1 41.1 4.1
15 5.6 29.4 4.4 38.6 5.8
20 5.1 28.7 5.7 37.7 7.5
40 4.2 27.5 11.0 36.2 14.5
CVA: Analytical variability evaluated according to the imprecision profile, as
previously reported [11].
RCV 95% and 99%: Reference Change Values calculated at the probability of
95% and 99% CI, respectively.
Δ Change 95% and 99%: Absolute critical change calculated at the probability
of 95% and 99%, respectively.
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4. Discussion
4.1. Analytical parameters and RCV of cTnI immunoassays
The results of the present study confirm that the Access cTnI
method, using DxI platform, shows analytical characteristics and per-
formances recommended by all international guidelines for high sen-
sitivity methods for cTn assay (Table 1) [11,23,24]. To best of our
Table 3
Mean, median, and percentile values of cTnI distribution values (ng/L) of the reference population.
Mean ± SD Median 25th percentile 75th percentile 97.5th percentile 99th percentile 99th perc. BS⁎ method (CI%)
































Fig. 2. Inter-relationship between log-cTnI concentration values (Y-axis) and
age (X-axis). In the figure, the linear regressions with sex is also indicated
(women: red color; men: blue color). (For interpretation of the references to
color in this figure legend, the reader is referred to the web version of this
article.)
Table 4
Regression analysis between cTnI values (dependent variable) and age and sex
(independent variables).
R2=0.227674 (P < .0001)
Intercept= 0.045 (SE 0.025) (P < .0001)
Age= 0.007 (SE 0.0005) (P < .0001)
Sex (F)=−0.082 (SE 0.007) (P < .0001)
SE: standard error
Fig. 3. The spline regression plot between cTnI concentrations (Y-axis) and age
(X-axis) is reported in the figure. The spline regression analysis shows the trend
between cTnI and age considering all the 1302 healthy subjects of the reference
population. The curvilinear trend was fitted by considering the mean values of
cTnI values of subjects with the same age interval.
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knowledge, this study report for the first time the RCV and absolute
critical change values of the Access cTnI method. The results reported
in Table 2 can be useful for the diagnosis of acute coronary syndrome in
patients presenting without persistent ST-segment elevation (NSTEMI),
the detection of myocardial injury in asymptomatic patients, and also
the evaluation of risk in the general population [1,3,4,26,27].
4.2. cTnI distribution values of reference population
The Fourth Universal Definition of Myocardial Infarction [3] states
that: “the term myocardial injury should be used when there is evidence
of elevated cardiac troponin values with at least one value above the
99th percentile URL”. Accordingly, the evaluation of 99th percentile
URL value of cTnI and cTnT has a fundamental relevance in the diag-
nosis of all cardiac diseases. Unfortunately, the accurate evaluation of
the 99th percentile value in the reference population presents some
important limitations, related to analytical performance of cTn
methods, demographic characteristic of reference populations, and
statistical approach used for calculation of distribution parameters
[15,16,28]. Indeed, large variations of 99th percentile URL values are
reported in the literature even for the same cTnI or cTnT immunoassay
method [15,16].
The results of the present study confirm that age and sex can
strongly affect the measurement of 99th percentile value, even when
the criteria for selection of reference population are well in accordance
with recommendations made by international guidelines [2,15]. In
particular, the results of the present study (as reported in Fig. 3) de-
monstrate that after the age of 55 years there is in both men and women
a progressive rise in cTnI concentrations, even when the healthy status
of the individuals enrolled in the study are well characterized using a
thorough clinical history together with laboratory (including assay of
BNP/NT-proBNP) and an accurate cardiac investigation (also including
ECG and echocardiography).
Sex-related 99th percentile URL values observed in this study, re-
ported by Pretorius et al. [24] and suggested by the manufacturer are
reported in Table 5. The results observed in the present study are well
in accordance with literature data because the 99th percentile URL
values of present study are included within the confidence interval
reported by Pretorius et al. [24] and manufacturer technical bulletin
(Table 5). The between-study bias of 99th URL values are probably due
to differences in age ranges, sample sizes, and sex-ratios of enrolled
healthy subjects.
The results of the present study are well in agreement with previous
results [28,29], indicating that both calculation of 99th percentile and
method to detect outliers can greatly affect the 99th percentile URL of
cTnI high-sensitivity methods. In this study both nonparametric boot-
strap approach and “Tukey's fences” method were used to reduce the
effect of outliers [22]. Indeed, the nonparametric bootstrap method
allowed significantly lower 99th percentile values than nonparametric
one for both whole population and subgroups related to age and sex
(mean ± SD: 11.3 ± 2.6 ng/L vs 15.7 ± 2.3 ng/L;N=7, P < .0001)
(Table 3). However, all 99th percentile values calculated with non-
parametric approach are within the 99% CI of those obtained with
nonparametric bootstrap method (Table 3). From a clinical point of
view, the use in the clinical practice of 99th percentile URL values,
calculated with nonparametric bootstrap method should theoretically
allow a better sensitivity but also a worse specificity both in detection
of myocardial injury and diagnosis of myocardial infarction [3]. Of
course, the relative cost/benefit of these two statistical approaches for
the calculation of the 99th percentile URL value of the Access cTnI
method should be evaluated by specifically designed clinical studies.
As previously reported in detail [11], the Access cTnI method sa-
tisfies the first fundamental criterium for high-sensitivity method for
cTnI assay. Indeed, the Access cTnI method measures the 99th per-
centile URL with an imprecision less than CV 10% (Table 1 and Fig. 1),
as requested by international guidelines [2]. The results, reported in the
present study, demonstrate that the Access cTnI method satisfies also
the second criterium for high-sensitivity method because it measures
cTn concentrations above the LoD in more than in 50% healthy subjects
of both men and women [2].
4.3. Strengths and limitations of the study
The strengths of this study are related to the experimental design.
Several Authors emphasized the need of both characterized reference
populations and standardized statistical approach to calculate cTnI 99th
percentiles [2,15,16,28,29]. Our study is a multi-center study which
enrolled a well selected healthy reference population according to in-
dications made by international guidelines and expert documents
[2,15]. The study reference population consisted of 1302 healthy adults
subjects with a large age range (18 to 86 years), and including 650
women and 652 men, well matched for age and sex-ratio. Furthermore,
for the calculation of 99th percentile URL values, the standard non-
parametric approach, as suggested by international guidelines [2], and
also the more complex, but also more accurate nonparametric bootstrap
method were used [22].
A relative limitation of this study is the low number of healthy
subjects with age > 55 years enrolled in this study (i.e., 570). This
number did not allow an accurate evaluation of the 99th percentile URL
values divided for men and women with age > 55 years. However, it is
well known that it is very difficult to enroll a great number of well
characterized healthy subjects with age>70 years [15,16].
5. Conclusions
The results of the present study confirm that the Access hsTnI
method using the UniCell DxI 800 platform satisfies all the criteria and
quality specifications required by the most recent international guide-
lines for high-sensitivity methods for cTn assay [2]. Furthermore, the
results of this study confirm that the calculation of the 99th percentile
URL values are greatly affected not only by age and sex of the reference
population, but also by the statistical approach used for calculation of
cTnI distribution parameters.
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